4 ms·
Derek's argument seems to be that some drugs may actually harm patients, and so Right to Try is bad. Isn't that known, and just something terminal patients nee
by oh_sigh 8y ago
Derek's argument seems to be that some drugs may actually harm patients, and so Right to Try is bad.
Isn't that known, and just something terminal patients need to balance with their doctors? If I had 6 months to live, I would probably roll the dice for a cure even if 50% of the time the drug would actually only give me 3 months to live.
I doubt anyone believes that trying experimental drugs can only help, and never hurt the patient. If that was the case we'd have been allowing experimental drug usage for a long time.
- AnimalMuppet 8y agoThere's two ways to look at this. If I've got six months to live, would I take a 50/50 gamble on living 20 years, where the downside is that I might only live 3 months? Probably - the expectation value of that gamble is highly positive. On the other hand, if you only have 6 months to live, 3 months is really a lot to lose... But I agree. This isn't a valid argument against Right to Try.
- nordsieck 8y agoThe proper way to look at this is a dynamic analysis, not a static analysis. For the first person to try the drug, it's a big gamble, but as each additional "right to try" participant takes the drug, everyone else gains knowledge as to its effectiveness. Is this as good as stage 3 trials at assuring safety? No. But you have to count all the people who could have been helped but weren't because of delays against a no right to try policy.
- jcranmer 8y ago> For the first person to try the drug, it's a big gamble, but as each additional "right to try" participant takes the drug, everyone else gains knowledge as to its effectiveness. The plural of anecdote is not data. We have come to understand what it takes to run a good study for effectiveness of a drug: double-blinded, randomized, high-power control studies, with further guards against p-hacking (did you fail a phase III but find a subgroup that was responsive? great, do another phase III on that subgroup; turns out it's mostly spurious). The data that comes from right-to-try is mostly not useful because it's not going to tell you how much of the benefit comes from things other than the drug (such as the placebo effect).
- olliej 8y agoCool, except right to try is not blinded -- you're paying to have access to drugs, so you have to get them. Any data from a person who buys a drug without knowing if it works or not (or kills them faster) is useless for everyone else (it actively reduces the trial population) due to placebo effect and trial controls. This is ignoring 50% being (i would say optimistic) for stage 3 trials, but right to try kicks in before stage 3 trials so suddenly you're dealing with stage 2 trials: and iirc only like 10% of candidates make it from stage 2 to stage 3, so now you've got maybe a 5% chance of it helping, and a much greater chance of it making your situation worse. And you're still not providing useful data that might help other people. It also ignores that there are typically multiple drugs with the same or similar targets running trials at the same time: which do you take given currently there's no evidence of which (or any) is effective, no data on how dangerous any (or all) of them are.
- eesmith 8y agoYour summary is incorrect. Lowe's position is stated at http://blogs.sciencemag.org/pipeline/archives/2018/05/25/federal-right-to-try http://blogs.sciencemag.org/pipeline/archives/2018/05/25/fed... . He writes: > I think Right to Try laws are largely useless, and have the potential to cause actual harm disproportionate to the good they might do. I think that there are sincere, principled advocates for them, but at the same time, there are many people on that side of the issue who are either ill-informed about medical research or who are simply grandstanding for votes and popular support. > In short, my biggest reasons for thinking this way are: (1) most investigational drugs don’t work. The failure rate in human clinical trials is around 90 per cent, and it’s been that way for a long time. (2) there are disease areas where a tragedy-of-the-commons situation will mean that controlled clinical trials (which are still the only way to determine if a new drug works) will be much more difficult to run under a “why wait for proof?” system (I have to note that the current bill restricts right-to-try to those patients who are ineligible for clinical trials, which is a good provision). (3) opening up unproven therapies could lead to a moral hazard, where it becomes lucrative to put useless-but-harmless “drug candidates” into “clinical trials” so you can charge desperate patients at “cost”. I mean every quotation mark in that last sentence. I am not the only person who thinks this way. My own suggestion for the last point has already been made: antioxidant phytonutrients – i.e., dried grape juice pills – for Alzheimer’s. Won’t do a thing, but hey, you have the right to try ’em. > There is empirical evidence for all of these positions. Many states have passed their own right-to-try laws (in various forms), and if there has been any decrease in human suffering or advance in medical knowledge through them, I have missed it. To get specific, when Colorado passed its own law in 2014, one of the first companies that announced plans to offer treatments under its provisions was a stem-cell company, Neuralstem. And guess what? None of their treatments ever worked. Most things don’t. Note that Lowe talked about harm which is disproportionate to the good, not the un-nuanced statement that that there may be harm and therefore bad, as you summarized it.
- Jach 8y ago>> controlled clinical trials (which are still the only way to determine if a new drug works) His objections are good, but this mindset will probably have to go in order to make headway on more efficient medicine. It would also alleviate the concern in #3, because once you give up that mindset, you actually have tools besides the (expensive) controlled clinical trial that allow you to make statements like "dried grape juice pills won't do a thing for Alzheimer's".
- jcranmer 8y agoThe problem with right-to-try is that it's framed as "Big Bad Pharma (and/or FDA's onerous regulations) is preventing these life-saving cures from getting to people, we need to get them sooner." Yet the experimental evidence is most drug candidates fail because they don't work. Even the big, expensive phase III trials have about a 50% failure rate. If you're pushing for access much earlier (concurrent with phase I), that means you're pushing for access before there's data on how lethal the drug is. Derek's big concern with right-to-try is that it's basically a way to advocate for taking the science out of drug approval. Data outside of a well-controlled study is hard to use, but the public will lobby for it to be used. And the concern isn't idle: when the FDA's response to the bill was "we're going to look into how to do this safely," the reply form a key Senator was "no, no, no, you don't understand, we're trying to tell you to get out of the way." The end goal would be to eliminate the FDA as useless bureaucracy, but we already have an example of what unregulated drug industry looks like: it's called the health supplements industry, which is so sleazy that many companies don't even bother to include the active ingredients they claim to include.
- olliej 8y agoDon't forget Thalidomide, etc. People seem to forget that there was a time where the FDA and trials didn't exist. And that the reason the FDA has to exist is because otherwise you get very expensive "drugs" that frequent, at best, do nothing, and oftentimes do harm.
- djrogers 8y ago> If you're pushing for access much earlier (concurrent with phase I) Nobody is doing that - current RTT legislation only applies to treatments that have passed phase I, not drugs that are in or have not yet started phase I trials.